XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.23.1

Goodwill and Intangible Assets, Net | 3 Months Ended
--- | ---
Mar. 31, 2023
Goodwill And Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets, Net | 6. Goodwill and Intangible Assets, Net During the three months ended March 31, 2023, the Company experienced a sustained decline in its stock price resulting in its market capitalization being less than the carrying value of its combined reporting units. The Company concluded the sustained decline in its stock price and decision to discontinue certain Cell Therapy clinical trials were triggering events during the quarter and performed a quantitative impairment test on goodwill and acquired IPR&D assets. Based on the results of the impairment analysis, the Company recognized a $29,633 goodwill impairment charge for the three months ended March 31, 2023, relating to the Cell Therapy reporting unit in its condensed consolidated statements of operations. During the three months ended March 31, 2022, no goodwill impairment was recognized. The carrying values of goodwill assigned to the Company’s reporting units are as follows:
|  | Cell Therapy |  |  | Biobanking |  |  | Degenerative Disease |  |  | Total |
Balance at December 31, 2022 |  | $ | 112,347 |  |  | $ | 7,347 |  |  | $ | - |  |  | $ | 119,694 |
Impairment(1) |  |  | (29,633 | ) |  |  | - |  |  |  | - |  |  |  | (29,633 | )
Balance at March 31, 2023 |  | $ | 82,714 |  |  | $ | 7,347 |  |  | $ | - |  |  | $ | 90,061 |
(1) As of March 31, 2023 and December 31, 2022, the accumulated goodwill impairment for the Degenerative Disease reporting unit was $3,610 and for Cell Therapy the accumulated goodwill impairment was $29,633 and $0 as of March 31, 2023 and December 31, 2022, respectively. Intangible Assets, Net Intangible assets, net consisted of the following:
|  | March 31, 2023 |  |  | December 31, 2022 |  |  | Estimated Useful Lives
Amortizable intangible assets: |  |  |  |  |  |  |  |
Developed technology |  | $ | 16,810 |  |  | $ | 16,810 |  |  | 11-16 years
Customer relationships |  |  | 2,413 |  |  |  | 2,413 |  |  | 10 years
Trade names & trademarks |  |  | 570 |  |  |  | 570 |  |  | 10-13 years
Reacquired rights |  |  | 4,200 |  |  |  | 4,200 |  |  | 6 years
|  |  | 23,993 |  |  |  | 23,993 |  |  |
Less: Accumulated amortization |  |  |  |  |  |  |  |
Developed technology |  |  | (6,839 | ) |  |  | (6,549 | ) |  |
Customer relationships |  |  | (1,501 | ) |  |  | (1,435 | ) |  |
Trade names & trademarks |  |  | (288 | ) |  |  | (275 | ) |  |
Reacquired rights |  |  | (3,412 | ) |  |  | (3,240 | ) |  |
|  |  | (12,040 | ) |  |  | (11,499 | ) |  |
Amortizable intangible assets, net |  |  | 11,953 |  |  |  | 12,494 |  |  |
Non-amortized intangible assets |  |  |  |  |  |  |  |
Acquired IPR&D product rights |  |  | 108,500 |  |  |  | 108,500 |  |  | indefinite
|  | $ | 120,453 |  |  | $ | 120,994 |  |  |
For the three months ended March 31, 2023 and 2022, amortization expense for intangible assets was $541 and $541, respectively. No impairment charges were recorded on intangible assets for the three months ended March 31, 2023 and 2022.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI https://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration